1262 related articles for article (PubMed ID: 18534918)
1. Nonmedical costs of colorectal cancer screening with the fecal occult blood test and colonoscopy.
Heitman SJ; Au F; Manns BJ; McGregor SE; Hilsden RJ
Clin Gastroenterol Hepatol; 2008 Aug; 6(8):912-917.e1. PubMed ID: 18534918
[TBL] [Abstract][Full Text] [Related]
2. Nonmedical costs of colorectal cancer screening using CT colonography.
Heitman SJ; Au F; Manns BJ; Pattison P; Hilsden RJ
J Am Coll Radiol; 2010 Dec; 7(12):943-8. PubMed ID: 21129685
[TBL] [Abstract][Full Text] [Related]
3. Many participants in fecal occult blood test population screening have a higher-than-average risk for colorectal cancer.
Worthley DL; Smith A; Bampton PA; Cole SR; Young GP
Eur J Gastroenterol Hepatol; 2006 Oct; 18(10):1079-83. PubMed ID: 16957514
[TBL] [Abstract][Full Text] [Related]
4. One-time screening for colorectal cancer with combined fecal occult-blood testing and examination of the distal colon.
Lieberman DA; Weiss DG;
N Engl J Med; 2001 Aug; 345(8):555-60. PubMed ID: 11529208
[TBL] [Abstract][Full Text] [Related]
5. Survey of internal medicine residents' use of the fecal occult blood test and their understanding of colorectal cancer screening and surveillance.
Sharma VK; Corder FA; Raufman JP; Sharma P; Fennerty MB; Howden CW
Am J Gastroenterol; 2000 Aug; 95(8):2068-73. PubMed ID: 10950059
[TBL] [Abstract][Full Text] [Related]
6. Survey of the opinions, knowledge, and practices of gastroenterologists regarding colorectal cancer screening and use of the fecal occult blood test.
Sharma VK; Corder FA; Fancher J; Howden CW
Am J Gastroenterol; 2000 Dec; 95(12):3629-32. PubMed ID: 11151904
[TBL] [Abstract][Full Text] [Related]
7. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics.
Allison JE; Sakoda LC; Levin TR; Tucker JP; Tekawa IS; Cuff T; Pauly MP; Shlager L; Palitz AM; Zhao WK; Schwartz JS; Ransohoff DF; Selby JV
J Natl Cancer Inst; 2007 Oct; 99(19):1462-70. PubMed ID: 17895475
[TBL] [Abstract][Full Text] [Related]
8. Periodic health examination, 1994 update: 2. Screening strategies for colorectal cancer. Canadian Task Force on the Periodic Health Examination.
Solomon MJ; McLeod RS
CMAJ; 1994 Jun; 150(12):1961-70. PubMed ID: 7980760
[TBL] [Abstract][Full Text] [Related]
9. Patient perceptions of stool-based DNA testing for colorectal cancer screening.
Schroy PC; Heeren TC
Am J Prev Med; 2005 Feb; 28(2):208-14. PubMed ID: 15710277
[TBL] [Abstract][Full Text] [Related]
10. Potential impact of population-based colorectal cancer screening in Canada.
Flanagan WM; Le Petit C; Berthelot JM; White KJ; Coombs BA; Jones-McLean E
Chronic Dis Can; 2003; 24(4):81-8. PubMed ID: 14733756
[TBL] [Abstract][Full Text] [Related]
11. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population.
Imperiale TF; Ransohoff DF; Itzkowitz SH; Turnbull BA; Ross ME;
N Engl J Med; 2004 Dec; 351(26):2704-14. PubMed ID: 15616205
[TBL] [Abstract][Full Text] [Related]
12. Randomized trial of different screening strategies for colorectal cancer: patient response and detection rates.
Segnan N; Senore C; Andreoni B; Arrigoni A; Bisanti L; Cardelli A; Castiglione G; Crosta C; DiPlacido R; Ferrari A; Ferraris R; Ferrero F; Fracchia M; Gasperoni S; Malfitana G; Recchia S; Risio M; Rizzetto M; Saracco G; Spandre M; Turco D; Turco P; Zappa M;
J Natl Cancer Inst; 2005 Mar; 97(5):347-57. PubMed ID: 15741571
[TBL] [Abstract][Full Text] [Related]
13. Limitations of the faecal occult blood test in screening for colorectal cancer.
Delcò F; Sonnenberg A
Ital J Gastroenterol Hepatol; 1999 Mar; 31(2):119-26. PubMed ID: 10363196
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness and economic impact of screening for colorectal cancer by mass fecal occult blood testing.
Helm JF; Russo MW; Biddle AK; Simpson KN; Ransohoff DF; Sandler RS
Am J Gastroenterol; 2000 Nov; 95(11):3250-8. PubMed ID: 11095350
[TBL] [Abstract][Full Text] [Related]
15. Prospective evaluation of fecal calprotectin as a screening biomarker for colorectal neoplasia.
Limburg PJ; Devens ME; Harrington JJ; Diehl NN; Mahoney DW; Ahlquist DA
Am J Gastroenterol; 2003 Oct; 98(10):2299-305. PubMed ID: 14572583
[TBL] [Abstract][Full Text] [Related]
16. The use of screening colonoscopy for patients cared for by the Department of Veterans Affairs.
El-Serag HB; Petersen L; Hampel H; Richardson P; Cooper G
Arch Intern Med; 2006 Nov; 166(20):2202-8. PubMed ID: 17101937
[TBL] [Abstract][Full Text] [Related]
17. A cost analysis of screening methodology for family members of colorectal cancer patients.
Rozen P; Ron E
Am J Gastroenterol; 1989 Dec; 84(12):1548-51. PubMed ID: 2512809
[TBL] [Abstract][Full Text] [Related]
18. Measuring the quality of colorectal cancer screening: the importance of follow-up.
Etzioni DA; Yano EM; Rubenstein LV; Lee ML; Ko CY; Brook RH; Parkerton PH; Asch SM
Dis Colon Rectum; 2006 Jul; 49(7):1002-10. PubMed ID: 16673056
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of mass screening for colorectal cancer: choice of fecal occult blood test and screening strategy.
Sobhani I; Alzahouri K; Ghout I; Charles DJ; Durand-Zaleski I
Dis Colon Rectum; 2011 Jul; 54(7):876-86. PubMed ID: 21654256
[TBL] [Abstract][Full Text] [Related]
20. [Preliminary report about the screening program for colorectal cancer by sequential fecal occult blood in Wuhan area for 4 years].
Lu ZM; Chen JG; Zhang YX; Wang Q; Xu J; Chen C; Yang R; Xiong F; Liu C; Peng XH
Zhonghua Wei Chang Wai Ke Za Zhi; 2009 Sep; 12(5):474-6. PubMed ID: 19742337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
